12:00 AM
Jun 11, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tetraxetan clivatuzumab: Final Phase Ib/II data

Final data from 90 evaluable patients with advanced inoperable pancreatic cancer in an open-label, dose-escalation, U.S. Phase Ib/II trial showed that multiple cycles of clivatuzumab plus gemcitabine (n=31) led to a combined median overall survival (OS) of 9.3 months, which the company said is comparable to other pancreatic cancer regimens. In 38 patients in the Phase Ib portion of the trial, 6.5 or 9 mCi/m 2 weekly clivatuzumab plus fixed-dose 200 mg/m 2 gemcitabine...

Read the full 348 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >